AI English summary of an SEC filing — figures as filed
Vertex Pharmaceuticals VRTXVertex said it entered into a merger agreement with Alpine Immune Sciences on April 10, 2024, under which its subsidiary Adams Merger Sub will launch a cash tender offer for all outstanding shares at $65.00 per share. The price is net to the seller, without interest and subject to applicable withholding taxes.
Key points
AI summaryVertex said it entered into a merger agreement with Alpine Immune Sciences on April 10, 2024, under which its subsidiary Adams Merger Sub will launch a cash tender offer for all outstanding shares at $65.00 per share. The price is net to the seller, without interest and subject to applicable withholding taxes.
The company said it will commence the tender offer within 10 business days after the date of the merger agreement, and that the offer will expire on the 20th business day after the commencement date. Conditions to completion include a majority of outstanding shares being tendered and the expiration of the Hart-Scott-Rodino Act waiting period. The transaction is not subject to a financing condition.
Vertex said that after the tender offer is completed, Adams Merger Sub will merge into Alpine Immune Sciences, which will survive as a wholly owned subsidiary of Vertex. Shares not tendered will be converted into the right to receive the offer price. Alpine Immune Sciences' unvested stock options and restricted stock units will fully vest immediately before the merger's effective time.
The company said stockholders including Frazier, Decheng Capital and OrbiMed-affiliated funds, which together own approximately 25.5% of the outstanding shares, agreed to tender all of their shares in the offer. If the merger agreement is terminated under specified circumstances, Alpine Immune Sciences may be required to pay Vertex a termination fee of $173 million.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Vertex to Acquire Alpine Immune Sciences for $65.00 Per Share in Cash
Vertex said it entered into a merger agreement with Alpine Immune Sciences on April 10, 2024, under which its subsidiary Adams Merger Sub will launch a cash tender offer for all outstanding shares at $65.00 per share. The price is net to the seller, without interest and subject to applicable withholding taxes.
Source · Based on the filing body and exhibits
Tender Offer Timing, Expiration and Closing Conditions
The company said it will commence the tender offer within 10 business days after the date of the merger agreement, and that the offer will expire on the 20th business day after the commencement date. Conditions to completion include a majority of outstanding shares being tendered and the expiration of the Hart-Scott-Rodino Act waiting period. The transaction is not subject to a financing condition.
Source · Based on the filing body and exhibits
Post-Tender Offer Merger Steps and Equity Award Treatment
Vertex said that after the tender offer is completed, Adams Merger Sub will merge into Alpine Immune Sciences, which will survive as a wholly owned subsidiary of Vertex. Shares not tendered will be converted into the right to receive the offer price. Alpine Immune Sciences' unvested stock options and restricted stock units will fully vest immediately before the merger's effective time.
Source · Based on the filing body and exhibits
Stockholder Tender Commitments and $173 million Termination Fee
The company said stockholders including Frazier, Decheng Capital and OrbiMed-affiliated funds, which together own approximately 25.5% of the outstanding shares, agreed to tender all of their shares in the offer. If the merger agreement is terminated under specified circumstances, Alpine Immune Sciences may be required to pay Vertex a termination fee of $173 million.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…